Application of compound CCCP in preparation of medicine for treating pulmonary fibrosis

CCCP, a simple compound, addresses the limitations of existing treatments by promoting macrophage autophagy to inhibit pulmonary fibrosis, offering a more effective treatment option.

CN119074714APending Publication Date: 2024-12-06JIANGNAN UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411285617.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-13
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Current anti-fibrotic drugs for pulmonary fibrosis, such as pirfenidone and nintedanib, are ineffective in curing the disease and consume significant medical resources, while existing small molecule inducers of macrophage autophagy have complex structures and are difficult to synthesize industrially.

Method used

The use of CCCP, a compound with a simple structure, to promote macrophage autophagy and treat pulmonary fibrosis through intraperitoneal injection, combined with pharmaceutically acceptable salts and various pharmaceutical excipients and carriers.

Benefits of technology

CCCP effectively promotes macrophage autophagy, reducing pulmonary fibrosis by inhibiting its progression and improving health outcomes in experimental models.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119074714A_ABST
    Figure CN119074714A_ABST
Patent Text Reader

Abstract

The invention discloses application of a compound CCCP in preparation of a medicine for treating pulmonary fibrosis, and belongs to the field of biological medicine. The invention provides an application of a compound CCCP or a pharmaceutically acceptable salt thereof in preparation of a medicine for treating macrophage autophagy mediated related diseases, and particularly relates to a method for promoting macrophage autophagy by using the compound CCCP or the pharmaceutically acceptable salt thereof as a macrophage autophagy inducer so as to inhibit pulmonary fibrosis.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biomedicine, and particularly relates to the application of the compound CCCP in preparing a drug for treating pulmonary fibrosis. Background Art

[0002] Idiopathic pulmonary fibrosis is a progressive and devastating lung disease with unknown etiology. Its pathological features are damage to alveolar epithelial cells and excessive deposition of extracellular matrix, which lead to irreversible fibrotic changes in the lung parenchyma structure and ultimately lead to the patient's death. In recent years, the incidence and mortality of pulmonary fibrosis have steadily increased. Although the current anti-fibrotic drugs pirfenidone and nintedanib can slow the progression of the disease, they cannot cure it and the prognosis is very unsatisfactory. They consume a lot of medical resources and seriously affect health conditions.

[0003] The pathological mechanism of pulmonary fibrosis is still unclear. A large number of studies have shown that in the pathological process of idiopathic pulmonary fibrosis, the activation and infiltration of immune cells can mediate tissue damage repair, inflammation and fibrosis reactions. Macrophages are the most important immune defense cells in lung tissue and play a key role in the pathological process of pulmonary fibrosis.

[0004] Autophagy is a conservative catabolic process that mediates the degradation of cytoplasmic organelles and proteins. Studies in recent years have confirmed that insufficient autophagy can regulate fibroblast aging and myofibroblast differentiation, and that autophagy has a key regulatory function in macrophage polarization and can participate in the phenotypic transformation of macrophages. Therefore, the development of drugs that promote macrophage autophagy is a potential method to improve pulmonary fibrosis.

[0005] The small molecule inducers currently reported to have the effect of promoting autophagy in lung macrophages are mainly sphingomyelinone derivatives (such as Chinese patent document CN108948036A). These compounds have complex structures and can only be obtained by microbial separation and extraction. Chemical synthesis is difficult, which is not conducive to industrial promotion. Summary of the invention

[0006] The present invention proposes a new treatment method, in which CCCP, a compound with a relatively simple structure, readily available raw materials, and significant differences from existing small molecule inducers, is used in the preparation of drugs for treating pulmonary fibrosis. The compound can effectively promote macrophage autophagy and improve pulmonary fibrosis.

[0007] The technical solution of the present invention is:

[0008] Use of compound CCCP or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis, wherein the compound has the structural formula:

[0009]

[0010] Use of the compound CCCP or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating macrophage autophagy-mediated related diseases.

[0011] The compound CCCP or a pharmaceutically acceptable salt thereof is used as a macrophage autophagy inducer to promote macrophage autophagy.

[0012] The compound CCCP or a pharmaceutically acceptable salt thereof is used for inhibiting pulmonary fibrosis.

[0013] The drug is a macrophage autophagy inducer.

[0014] The drug is administered by intraperitoneal injection.

[0015] The dosage of the drug for experimental animals is 10 mg / kg.

[0016] The pharmaceutically acceptable salt is an inorganic salt or an organic salt; wherein the inorganic salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; and the organic salt is selected from formates, acetates, trifluoroacetates, propionates, pyruvates, glycolates, oxalates, malonates, succinates, glutarates, fumarates, maleates, lactates, malates, citrates, tartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, salicylates, p-toluenesulfonates, and ascorbates.

[0017] In one embodiment of the present invention, the drug contains pharmaceutical excipients.

[0018] The pharmaceutical excipients include: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, and wetting agents.

[0019] The pharmaceutical excipients also include: osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids and release retardants.

[0020] In one embodiment of the present invention, the medicament comprises a pharmaceutically acceptable carrier.

[0021] The drug carrier is selected from microcapsules, microspheres, nanoparticles and liposomes.

[0022] In one embodiment of the present invention, the dosage forms of the drug include: injection, lyophilized powder for injection, suspension, implant, embolic agent, capsule, tablet, pill and oral solution.

[0023] Beneficial effects:

[0024] The CCCP described in the present invention is a novel effective inducer of macrophage autophagy. By using in vitro and in vivo models, the applicant systematically studied the potential therapeutic effect of CCCP on pulmonary fibrosis, and experimentally verified that CCCP improves pulmonary fibrosis by promoting macrophage autophagy. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 CCCP promotes macrophage autophagy recovery;

[0026] Figure 2 H&E staining of lung tissue of mice after CCCP alleviated bleomycin-induced

[0027] Figure 3 This is the Masson staining image of CCCP-induced relief of bleomycin-induced lung tissue in mice;

[0028] Figure 4 CCCP alleviated the mRNA expression levels of α-SMA and Fibronectin in the lung tissue of mice induced by bleomycin.

[0029] Figure 5 These are the pathological evaluation results of the degree of pulmonary fibrosis in mice. DETAILED DESCRIPTION

[0030] Related experimental reagents involved in the present invention:

[0031] Bleomycin (BIOTANG, USA); LC3 primary antibody (abcam, USA); β-actin primary antibody (abcam, USA); anti-rabbit secondary antibody (abcam, USA); collagenase (Roche Diagnostics, USA); DNase (Sigma-Aldrich, USA); protein lysis buffer (Biyotime, China); BCA protein assay kit (Biyotime, China); Masson staining kit (Nanjing Jiancheng Technology Co., Ltd.); hematoxylin-eosin (H&E) staining solution (Nanjing Jiancheng Technology Co., Ltd.); qPCR RT Kit (TOYOBO, Japan); qPCR MasterMix kit (DBI, Germany); CCCP compound (Taoshu Biological Co., Ltd.); other reagents were of biological grade or analytical grade.

[0032] Example 1 Application of compound CCCP in the preparation of drugs for treating pulmonary fibrosis

[0033] 1. Experimental Animal Handling

[0034] Male wild-type mice aged 6-8 weeks were given an intraperitoneal injection of sodium pentobarbital (50 mg / kg). After anesthesia, the neck skin was disinfected with 75% ethanol, and a 0.5-1 cm laceration was cut longitudinally in the neck with scissors. The neck muscles were bluntly separated to expose the trachea. The indwelling needle was inserted from the mouth into the trachea to the bronchus of the lung. A 200 μl pipette was used to draw bleomycin solution (1.4 U / kg body weight for pulmonary fibrosis model) or saline to the indwelling needle port, and 500 μl of air was quickly injected into the lungs, and the wound was sutured. The same volume of saline was injected into the trachea of ​​mice as the control group. The modeled mice were randomly divided into two groups (6 mice in each group)

[0035] Bleomycin group: mice were given 1.4 U / kg bleomycin via trachea to induce pulmonary fibrosis.

[0036] Bleomycin + CCCP group: Mice with bleomycin-induced pulmonary fibrosis began to receive CCCP treatment on the 8th day.

[0037] CCCP was prepared into a 5 mg / mL stock solution, and the solvent contained 5% DMSO+30% PEG 300+dd Water. Starting from the 8th day, 10 mg / kg CCCP was injected intraperitoneally into the mice in the bleomycin+CCCP group every other day. On the 21st day, the mice were anesthetized and sampled. The skin was disinfected with 75% ethanol, and an opening was made in the middle of the chest and abdomen to fully expose the chest cavity. PBS was injected from the right ventricle to flush until the lung tissue turned white. The junction between the heart and the left lung was ligated, and 4% paraformaldehyde was perfused into the left lung through the trachea, and the trachea was ligated. The left lung was cut and immersed in 4% paraformaldehyde for fixation; part of the remaining lung tissue was stored in liquid nitrogen, and part was reserved for extraction of pulmonary interstitial macrophages. After fixing the left lung with 4% paraformaldehyde solution for 24 hours, the tissue was immersed in 80%, twice 95%, and twice 100% ethanol solution for 1 hour each to dehydrate the tissue, then immersed in xylene solution twice for 20 minutes each to make it transparent, and then immersed in paraffin wax tanks three times for 1 hour. The tissue was then embedded in wax liquid to make a wax block.

[0038] Preparation of pulmonary interstitial macrophages: mince the lungs with scissors and digest the whole lung tissue from the mouse by collagenase. Incubate at 37°C for 40 minutes in a digestion buffer containing 10% fetal bovine serum, 1mg / ml collagenase, and 30μg / ml DNase. Remove the red blood cells from the total lung cells with red blood cell lysis buffer and rinse with PBS. Let the total lung cells be cultured on a serum-free adhesion culture dish for 1 hour, remove the supernatant, and the adherent cells are the pulmonary interstitial macrophages.

[0039] 2. Compound CCCP promotes macrophage autophagy recovery

[0040] Mouse pulmonary interstitial macrophages were lysed with protein lysis buffer and placed on ice for full homogenization. Then placed in a centrifuge for 15 minutes at 12000rpm, and the supernatant was transferred to a new EP tube. The protein concentration was determined using a BCA protein assay kit. After unifying the concentration, loading buffer was added, and electrophoresis was performed in a 95℃ metal bath for 10 minutes. The membrane was transferred and blocked with 5% BSA for 1 hour. LC3 and β-actin primary antibodies were added respectively, and incubated in a refrigerator at 4 degrees overnight. The primary antibodies were recovered the next day, and anti-rabbit secondary antibodies were added for incubation at room temperature for 1 hour for development.

[0041] The results are as follows Figure 1 As shown, the bleomycin group inhibited the autophagy of pulmonary interstitial macrophages, while CCCP was able to restore their autophagy.

[0042] 3. Compound CCCP alleviates bleomycin-induced H&E staining of mouse lung tissue

[0043] The mouse lung tissue wax block was sliced ​​to a thickness of 4 μm. After drying, it was dewaxed with xylene, 100%, 95%, 90%, 80%, and 70% alcohol, and the dewaxed slices were immersed in hematoxylin staining solution for 5-10 minutes (the staining time was determined by the color), the slices were rinsed with tap water, and the color was differentiated with 1% hydrochloric acid ethanol solution, and then the blue was returned with 1% ammonia solution, and immersed in eosin solution for 15 seconds to 1 minute (the staining time was determined by the color), and the excess dye was rinsed with tap water, and then the slices were placed in 70%, 80%, 95%, 95%, 100%, 100%, xylene I and xylene II solutions for 3 minutes each, and after drying, the slices were sealed with neutral gum and placed under an upright microscope for observation and photography.

[0044] The results are as follows Figure 2 As shown in the figure, it can be seen that after the bleomycin group was treated with CCCP, the degree and area of ​​pulmonary fibrosis in mice were significantly reduced.

[0045] 4. Compound CCCP alleviates bleomycin-induced lung tissue Masson staining of mice

[0046] The mouse lung tissue wax block was sliced ​​to a thickness of 4 μm. After drying, it was dewaxed with xylene, 100%, 95%, 90%, 80%, and 70% alcohol, and the slices were stained according to the Masson staining kit instructions of Nanjing Jiancheng Biological Company:

[0047] 1) Wet the slide with distilled water for 30 to 60 seconds before staining;

[0048] 2) Stain with R1 nuclear stain for about 60 seconds, discard, and rinse with rinse solution for about 30 seconds;

[0049] 3) Dye with R2 slurry for about 30 to 60 seconds, discard, and rinse with rinse solution for about 30 seconds;

[0050] 4) Use R3 yellow color separation solution to separate for about 6 to 8 minutes, then discard the color separation solution and directly stain with R4 blue counterstain solution for about 5 minutes, discard, and rinse with anhydrous ethanol; after drying, directly seal the slide with neutral gum.

[0051] Place the specimen under an upright microscope for observation and photography.

[0052] The results are as follows Figure 3 As shown in the figure, it can be seen that after the bleomycin group was treated with CCCP, the degree and area of ​​pulmonary fibrosis in mice were significantly reduced.

[0053] 5. Compound CCCP reduces the mRNA expression levels of α-SMA and Fibronectin in mouse lung tissue after bleomycin-induced

[0054] A small amount of mouse lung tissue was taken from each group; 1 ml Trizol was added, and the mixture was homogenized using an electric homogenizer on ice, and then placed at room temperature for 5 minutes to allow for complete lysis, centrifuged at 4°C 12000 rpm for 5 minutes, the supernatant was taken, 200 μl chloroform was added, the mixture was mixed and placed at room temperature for 2 minutes; centrifuged at 4°C 12000 g for 15 minutes, and the upper aqueous phase was carefully aspirated into another centrifuge tube; 0.5 ml isopropanol was added to each tube and mixed, the mixture was placed at room temperature for 5-10 minutes, centrifuged at 4°C 12000 g for 10 minutes, and the supernatant was removed; 1 ml 75% ethanol prepared with DEPC water was added for washing, centrifuged at 4°C 12000 g for 5 minutes, the supernatant was discarded, the mixture was dried at room temperature, and 50 μl RNase-free water-soluble RNA was used; a microplate reader was used for quantification, and an OD260 / OD280 ratio of 1.8-2.0 indicated that the RNA purity was high, and all samples were stored at -80°C for future use. Reverse transcription: Take 1ng of the above RNA, add 0.5μl Random primer, 0.5μl Enzyme mix, 2μl 5x buffer and RNase-free water to a total of 10μl reaction system; place in a PCR instrument for reverse transcription at 37℃, react for 1 hour, and immediately place in 98℃ for 5 minutes to inactivate the enzyme. The resulting product is cDNA, which is used for q-PCR reaction or stored at -20℃. Fluorescence quantitative PCR experiment: Calculate the concentration of the above reverse transcribed cDNA and take 2ng of the volume as a template, add 1μl specific detection primer, 10μl 2x MasterMix (SYBR Green) and distilled water to a total of 20μl reaction system; place in a fluorescence quantitative PCR instrument, the reaction conditions are: 95℃ for 2 minutes; 95℃ for 15 seconds, 55℃ annealing for 30 seconds (annealing temperature is adjusted according to the primer TM value), 72℃ extension for 20 seconds for a total of 40 cycles; then 95℃ for 15 seconds, 60℃ for 15 seconds for 20 minutes. The mouse gene primer sequences detected in this experiment are as follows:

[0055] α-SMA: upstream primer, 5'-GACGCTGAAGTATCCGATAGAACACG-3',

[0056] Downstream primer, 5′-CACCATCTCCAGAGTCCAGCACAAT-3′.

[0057] Fibronectin: upstream primer, 5'-TCTGGGAAATGGAAAAGGGGAATGG-3',

[0058] downstream primer, 5′-CACTGAAGCAGGTTTCCTCGGTTGT-3′;

[0059] The experimental data in this part are expressed as mean ± SEM of more than 6 independent experiments. The experimental data were processed using GraphpadPrism6.0 software, and the data between groups were compared using one-way ANOVA or two-way ANOVA with post-hoc student t test. P < 0.05 indicated that the results were statistically significant. Figure 4 As shown in the figure, it can be seen that after the bleomycin group was treated with CCCP, the α-SMA and Fibronectin in the lung tissue of mice were significantly reduced.

[0060] 6. Pathological evaluation of pulmonary fibrosis in compound mice

[0061] Ashcroft score was used to show the pulmonary fibrosis scores among the groups. The experimental data were processed using Graphpad Prism6.0 software. The data among the groups were compared using one-way ANOVA or two-way ANOVA with post-hoc student t test.

[0062] The results are as follows Figure 5 As shown in the figure, it can be seen that after the bleomycin group was treated with CCCP, the pathological scores in the lung tissues of mice were significantly reduced.

[0063] These results indicate that CCCP can reduce bleomycin-induced pulmonary fibrosis.

[0064] The embodiments provided above are not intended to limit the scope of the present invention, and the steps described are not intended to limit the execution order thereof. Those skilled in the art may make obvious improvements to the present invention in combination with existing common knowledge, which also fall within the scope of protection defined by the claims of the present invention.

Claims

1. Use of compound CCCP or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis, wherein the compound has the structural formula:

2. Use of compound CCCP or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating macrophage autophagy-mediated related diseases.

3. The use according to claim 1 or 2, It is characterized in that The compound CCCP or a pharmaceutically acceptable salt thereof is used as a macrophage autophagy inducer to promote macrophage autophagy.

4. The use according to claim 1 or 2, It is characterized in that The pharmaceutically acceptable salt is an inorganic salt or an organic salt; wherein the inorganic salt is selected from hydrochloride, hydrobromide, hydroiodide, perchlorate, sulfate, bisulfate, nitrate, phosphate, and acid phosphate; and the organic salt is selected from formates, acetates, trifluoroacetates, propionates, pyruvates, glycolates, oxalates, malonates, succinates, glutarates, fumarates, maleates, lactates, malates, citrates, tartrates, methanesulfonates, ethanesulfonates, benzenesulfonates, salicylates, p-toluenesulfonates, and ascorbates.

5. The use according to claim 1 or 2, It is characterized in that The medicine contains pharmaceutical excipients.

6. The use according to claim 5, It is characterized in that The pharmaceutical excipients include: solvents, propellants, solubilizers, cosolvents, emulsifiers, colorants, adhesives, disintegrants, fillers, lubricants, and wetting agents.

7. The use according to claim 5, It is characterized in that The pharmaceutical excipients also include: osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, coating materials, fragrances, anti-adhesive agents, integrators, penetration enhancers, pH regulators, buffers, plasticizers, surfactants, foaming agents, defoamers, thickeners, inclusion agents, humectants, flocculants and deflocculating agents, filter aids and release retardants.

8. The use according to claim 1 or 2, It is characterized in that The medicine comprises a pharmaceutically acceptable carrier.

9. The use according to claim 8, It is characterized in that The drug carrier is selected from microcapsules, microspheres, nanoparticles and liposomes.

10. The use according to claim 1 or 2, It is characterized in that The dosage forms of the drug include injection, freeze-dried powder for injection, suspension, implant, embolic agent, capsule, tablet, pill and oral solution.

Citation Information

Patent Citations

  • Application of compound UMI-77 in preparation of medicine for treating pulmonary fibrosis

    CN116077479A

  • Aging cell lysis compounds and compositions

    CN116546960A